zinc finger protein 29, pseudogeneGenealiases: KOX26 · ZNF29
Q-omics provides the consensus-scored ZNF29P profile across patient tissues and cancer cell-line models. ZNF29P expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, ZNF29P is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, ZNF29P RNA expression shows 13,996 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight CESC, KIRC, and DLBC as cancer lineages where ZNF29P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF29P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF29P survival associations across molecular data types. ZNF29P RNA expression shows survival associations in the most cancer types (17), followed by mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF29P RNA expression–survival associations across cancer types. High ZNF29P expression shows unfavorable associations in CESC, CHOL, COAD, UCEC, KIRC and THCA. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for ZNF29P RNA expression.
This table summarizes ZNF29P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF29P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF29P shows lower tumor expression in THCA and higher tumor expression in KIRC, LUSC, STAD, CHOL and HNSC. The KIRC box plot shows higher ZNF29P RNA expression in tumor versus normal tissue (log2 FC = +0.292, t-test p = .001).
This table shows molecular features associated with ZNF29P in patient tissues and cancer cell lines. In patient samples, ZNF29P shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
